23 completed, 7 recruiting, 5 unknown, 4 terminated. 45 Phase 2, 10 Phase 3, 4 Phase 1.
Follow Hypertrophy: new trials by email Literature Review of Hypertrophy trials Research Report on Hypertrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ATR 1072 in Participants With PRKAG2 Syndrome ATR 1072 - Cardiac Glycogenosis, Cardiomyopathy | Phase 1 / Phase 2 | Recruiting | Atrium Therapeutics | 37 | 2026-09-14 | 2026-09-18 |
| Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy LX2006, Usual Care - Friedreich Ataxia, Cardiomyopathy, Secondary | Phase 2 | Recruiting | Lexeo Therapeutics | 26 | 2026-06-25 | 2026-09-02 |
| Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF [ARNI + SGLTi + AMR], [SGLTi + previously taken RAAS blocker] - HFpEF, LVDD | Phase 2 | Recruiting | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | 50 | 2025-03-18 | 2026-04-24 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam - Splenomegaly, Myelofibrosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-10-01 | 2026-09-16 |
| Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars Intralesional enalaprilat injection - Hypertrophic Scar | Phase 2 / Phase 3 | Withdrawn | Nova Scotia Health Authority | 2024-08-01 | 2025-02-17 | |
| MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies Trametinib tablet, Standard therapy - Cardiomegaly, Noonan Syndrome | Phase 2 | Recruiting | Medical University of Warsaw | 40 | 2024-08-01 | 2024-08-15 |
| Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy CDR132L, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 | Withdrawn | Cardior Pharmaceuticals GmbH | 2024-04-30 | 2026-07-07 | |
| The COLchicine HEART Failure PRESERVED Trial (COLHEART-PRESERVED) Colchicine, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 | Unknown | Tor Biering-Sørensen | 152 | 2024-01-18 | 2024-02-28 |
| A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease RP-A501 - Danon Disease | Phase 2 | Recruiting | Rocket Pharmaceuticals Inc. | 18 | 2023-09-05 | 2026-10-06 |
| Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Valsartan, Placebo Oral Tablet - Aortic Valve Stenosis, Valsartan | Phase 2 / Phase 3 | Withdrawn | University Hospital, Limoges | 2023-01-02 | 2023-03-17 | |
| SGLT2 Inhibition in Hemodialysis Dapagliflozin 10 MG, Placebo - Kidney Failure, Hemodialysis | Phase 2 | Completed | Medical University of Vienna | 220 | 2022-10-01 | 2026-03-03 |
| Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI SGLT-2 inhibitors, Placebo - Heart Attack, Enlarged Heart | Phase 2 | Recruiting | Minneapolis Heart Institute Foundation | 81 | 2022-08-03 | 2024-10-08 |
| Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention SGLT2 inhibitor, Placebo - Aortic Stenosis, Left Ventricle Hypertrophied | Phase 2 / Phase 3 | Unknown | University of Aarhus | 106 | 2022-02-12 | 2022-02-15 |
| The COlchicine HypERtENsion Trial Colchicine, Placebo - Hypertension | Phase 2 | Active not recruiting | Herlev and Gentofte Hospital | 150 | 2021-08-10 | 2025-12-22 |
| Role of Perhexiline in Hypertrophic Cardiomyopathy Perhexiline, Placebo - Hypertrophic Cardiomyopathy | Phase 2 | Unknown | Flinders University | 60 | 2020-12-01 | 2021-03-11 |
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Ruxolitinib - BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells | Phase 2 | Active not recruiting | Stanford University | 8 | 2019-11-15 | 2026-09-01 |
| LCZ696 in Advanced LV Hypertrophy and HFpEF LCZ 696, Valsartan - Heart Failure, Essential Hypertension | Phase 2 | Completed | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | 61 | 2019-05-31 | 2025-05-25 |
| S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Isatuximab, Laboratory Biomarker Analysis - Amorphous, Eosinophilic, and Acellular Deposit, Constipation | Phase 2 | Completed | SWOG Cancer Research Network | 43 | 2018-06-06 | 2025-09-09 |
| A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 2 | Completed | AbbVie | 191 | 2017-10-31 | 2026-01-20 |
| Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Rigosertib, Questionnaire - Leukemia, Myelofibrosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2017-08-16 | 2020-08-07 |
Showing 20 of 45. Sign in to see all of them.
Hypertrophy, Left Ventricular (18) · Cardiomegaly (9) · Cardiomyopathy, Hypertrophic (8) · Heart Failure (8) · Splenomegaly (8) · Cardiomyopathies (7) · Hepatomegaly (6) · Heart Diseases (5) · Cardiovascular Diseases (4) · Hypertension (4) · Primary Myelofibrosis (4) · Aortic Valve Stenosis (3) · Liver Diseases (3) · Polycystic liver disease (3)
Pathological Conditions, Anatomical (45) · Pathological Conditions, Signs and Symptoms (45) · Cardiovascular Diseases (27) · Heart Diseases (26) · Cardiomegaly (18) · Aortic Valve Disease (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Heart Valve Diseases (11) · Genetic Diseases, Inborn (9) · Pathologic Processes (9) · Vascular Diseases (9) · Aortic Stenosis, Subvalvular (8) · Aortic Valve Stenosis (8) · Hemic and Lymphatic Diseases (8)
ruxolitinib (4) · Blood Specimen Collection (2) · Colchicine (2) · Perhexiline (2) · Sodium-Glucose Transporter 2 Inhibitors (2) · Tadalafil (2) · Valsartan (2) · lanreotide (2) · Atenolol (1) · Busulfan (1) · Cyclophosphamide (1) · Cyclosporine (1) · Diltiazem (1) · Enalaprilat (1) · Irbesartan (1)
M.D. Anderson Cancer Center (4) · Andrea M. Isidori (2) · Celladon Corporation (2) · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation (2) · Radboud University Medical Center (2) · AbbVie (1) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · Atrium Therapeutics (1) · Brigham and Women's Hospital (1) · Cardior Pharmaceuticals GmbH (1) · Flinders University (1) · Gilead Sciences (1) · Henning Bundgaard (1) · Herlev and Gentofte Hospital (1) · Jean-Luc Balligand (1)
United States (20) · United Kingdom (8) · Italy (7) · Denmark (5) · Germany (5) · Netherlands (5) · Belgium (4) · Poland (4) · Australia (3) · Canada (3) · France (3) · Greece (3) · Israel (3) · Hungary (2) · Russia (2)
Elisa Giannetta, MD - Phd (2) · Frederik Nevens, MD, PhD (2) · Loes van Keimpema, MSc (2) · Amrita Ahulwalia, BSc PhD (1) · Azim S Gangji, MD MSc FRCPC (1) · Barry Greenberg, MD (1) · Camilla Ikast Ottosen, MD (1) · Carolyn Y Ho, MD (1) · Christoph Wanner, MD (1) · Domeinco Pagano, MD FRCS (1) · Emma Scott (1) · Fabian Hammer, MD, PhD (1)
PMID 39356039, PMID 11403367, PMID 12172314, PMID 12423712, PMID 14639093, PMID 14700505, PMID 14704728, PMID 15253184, PMID 15716707, PMID 16079683, PMID 16942935, PMID 17444886, PMID 17637792, PMID 17762662, PMID 18464745, PMID 19106243, PMID 19486119, PMID 19621835, PMID 21632446, PMID 22773240, PMID 24084214, PMID 24166468, PMID 24622121, PMID 25533774, PMID 26166166, PMID 26661322, PMID 26803443, PMID 27590665, PMID 30087573, PMID 31385893, PMID 31969369, PMID 32938484, PMID 33544240, PMID 33586138, PMID 34656640, PMID 35180010, PMID 35576960, PMID 37728907, PMID 40041314, PMID 40121452, PMID 40454409, PMID 40517417, PMID 40925099, PMID 41430169, PMID 41846295, PMID 42210033, PMID 42842696, PMID 7917152
2015 (2), 2017 (1), 2025 (1), K23HL078901 (1), P30CA016672 (1), U10CA180888 (1), UL1RR024150 (1)